EUVIMEDEUVIMED entdecken
Crossref

Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer

Gaoqi Xu, Dihong Yang, Haiying Ding, Like Zhong, Junfeng Zhu, Xiufang Mi, Xueyuan Zhang, Zhufeng Wu, Wenxiu Xin, Chunlei Li, Jiaqi Wang, Luo Fang

European Journal of Clinical Pharmacology · 2024

DOI: 10.1007/s00228-024-03711-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Gaoqi Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Mitoxantrone, Liposomes, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study is aimed at investigating the pharmacokinetic (PK) characteristics of pegylated liposomal mitoxantrone (PLM) in patients with relapsed/refractory lymphoma or small cell lung cancer (SCLC) by constructing population pharmacokinetic (popPK) models for both liposome-encapsulated mitoxantrone and free mitoxantrone. METHODS: A total of 23 patients with relapsed/refractory lymphoma and 42 patients with SCLC were included. A popPK model was simultaneously developed utilizing a non-linear mixed effects model (NONMEM) to explore the PK profiles of liposome-encapsulated mitoxantrone and free mitoxantrone. Clearance (CL) and distribution volume (V) were calculated, and covariate analysis was employed to evaluate the influence of patient disease type, demographic information, and biochemical indicators of liver and kidney function on PK parameters. RESULTS: The concentration-time profiles for both liposome-encapsulated mitoxantrone and free mitoxantrone were described by a one-compartment model. The release (Rel) of liposome-encapsulated mitoxantrone to free mitoxantrone was determined to be 0.0191 L/h, and the V of liposome-encapsulated mitoxantrone was 2.32 L. The apparent CL of free mitoxantrone was estimated at 1.66 L/h. The apparent V of free mitoxantrone was 35.8 L in patients with relapsed/refractory lymphoma and 22.2 L for patients with SCLC. In patients with relapsed/refractory lymphoma, lower maximum concentration (Cmax) and higher apparent V of free mitoxantrone were observed compared with patients with SCLC. CONCLUSION: The popPK characteristics of both liposome-encapsulated and free mitoxantrone in patients with relapsed/refractory lymphoma or SCLC were effectively described by a one-compartment model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitoxantroneLiposomesSmall Cell Lung CarcinomaLung NeoplasmsModels, BiologicalHumansMaleMiddle AgedFemaleAgedAdultLymphomaAntineoplastic AgentsAged, 80 and overPolyethylene Glycols

Stichwörter der Autor:innen

Pegylated liposome mitoxantronePopulation pharmacokineticsRelapsed/refractory lymphomaSmall cell lung cancer

Substanzen

MitoxantroneLiposomesAntineoplastic AgentsPolyethylene Glycols

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei, 050035, China.
  • CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei, 050035, China. lchunlei@cspc.cn.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. wangjq@zjcc.org.cn.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. fangluo@zjcc.org.cn.

Zitieren

APA

Xu, G., Yang, D., Ding, H., Zhong, L., Zhu, J., Mi, X., Zhang, X., Wu, Z., Xin, W., Li, C., Wang, J., & Fang, L. (2024). Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03711-8

Vancouver

Xu G, Yang D, Ding H, Zhong L, Zhu J, Mi X, et al. Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03711-8

BibTeX
@article{Xu2024,
  author = {Xu, Gaoqi and Yang, Dihong and Ding, Haiying and Zhong, Like and Zhu, Junfeng and Mi, Xiufang and Zhang, Xueyuan and Wu, Zhufeng and Xin, Wenxiu and Li, Chunlei and Wang, Jiaqi and Fang, Luo},
  title = {Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer},
  journal = {European Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1007/s00228-024-03711-8}
}
Kostenlos starten →